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Predicting the Risk of a Second Basal Cell Carcinoma
Joris A.C. Verkouteren1,4, Hilde Smedinga2,4, Ewout W. Steyerberg2, Albert Hofman3 and Tamar Nijsten1
A third of basal cell carcinoma (BCC) patients will develop subsequent BCCs. We aimed to develop a simple
model to predict the absolute risk of a second BCC. We observed 14,628 participants of Northern European
ancestry from a prospective population-based cohort study. BCCs were identiﬁed using a linkage with the Dutch
Pathology Registry (Pathological Anatomy National Automated Archive). Predictors for a second BCC included 13
phenotypic, lifestyle, and tumor-speciﬁc characteristics. The prediction model was based on the Fine and Gray
regression model to account for the competing risk of death from other causes. Among 1,077 participants with at
least one BCC, 293 developed a second BCC at a median of 3 years. Several well-known risk factors for a ﬁrst BCC
were not prognostic for a second BCC, whereas having more than one initial BCC was the strongest predictor.
Discriminative ability at 3 years was reasonable (bootstrap validated c-index= 0.65). Three groups were created,
with 7, 12, and 28% risk of a second BCC within 3 years. We conclude that a combination of readily available
clinical characteristics can reasonably identify patients at high risk of a second BCC. External validation and
extension with stronger predictors is desirable to further improve risk prediction.
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INTRODUCTION
Patients with previously treated basal cell carcinoma (BCC)
have a high risk of subsequent BCCs (Epstein, 1973). A recent
meta-analysis showed that 29% of the patients with a ﬁrst
BCC will develop at least one more BCC (Flohil et al., 2013b).
The increasing incidence of BCC, with ~ 5% annually,
suggests that primary prevention campaigns have not been
very effective so far (Lomas et al., 2012). Secondary prevention
(i.e., detecting new BCCs at an early stage among patients with a
prior BCC) is important to reduce the high disease burden (i.e.,
morbidity and costs) associated with this very common cancer
(Housman et al., 2003; Flohil et al., 2013a; Hollestein et al.,
2014).
The most well-known risk factor for a BCC is UVR, in
particular acute and intermittent exposure (Kricker et al., 1995;
Armstrong and Kricker, 2001). Recently, Weinstock coined the
term “actinic neoplasia syndrome” to underline the fact that
patients with a keratinocyte carcinoma (BCC or squamous cell
carcinoma) frequently develop another keratinocyte carcinoma
and various other signs of cutaneous photodamage (e.g., solar
keratosis and actinic keratosis) due to the ﬁeld dysplasia
(Weinstock et al., 2009). However, BCC is a complex disease
and not only UVR-related factors are important in its
carcinogenesis.
In contrast to risk factors for a ﬁrst BCC, prognostic factors
for a second BCC are less well documented. Male sex, higher
age at initial BCC, and a history of BCC have been found
associated with metachronous BCCs (Karagas et al., 1992;
Richmond-Sinclair et al., 2010; Flohil et al., 2011). The value
of other phenotypic (e.g., skin type) and environmental (e.g.,
UVR) characteristics in predicting a new BCC is under debate
(Robinson, 1987; Karagas et al., 1992; Lovatt et al., 2005;
Kiiski et al., 2010; Richmond-Sinclair et al., 2010). However,
no prediction models have been developed yet that allow for
individualized risk stratiﬁcation.
The objective of this study is to develop a prognostic model
for predicting the occurrence of a second BCC. We hereto
analyzed a prospective population-based cohort (Rotterdam
Study; RS) including over a 1,000 BCC patients.
RESULTS
Study population
After the linkage between Pathological Anatomy National
Automated Archive (PALGA) and the RS, 1,528 patients with
at least one BCC were identiﬁed. Of those, 451 were
excluded because they developed at least one BCC before
entry of the RS. Overall, 1,077 patients were included, of
whom 293 developed a second BCC during a median follow-
up of 3.0 years, 479 did not develop a new BCC before the
end of follow-up (median 3.8 years), and 305 died before they
reached the end of follow-up (median 4.6 years; Table 1). The
median age at ﬁrst BCC in the overall group was 74.5 years,
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whereas in the group of participants who died it was 80.0
years. In all groups, there were more females than males.
Age at ﬁrst BCC diagnosis
When using ordinary Cox models, there appeared a nonlinear
relationship between age at ﬁrst BCC diagnosis and the
hazard of developing a second BCC (Figure 1a) and a linear
relationship between age and the hazard of dying (Figure 1b).
The subdistribution hazard of a second BCC—using the Fine
and Gray model—also had a nonlinear relationship with age
(Figure 1c). Compared with the cause-speciﬁc hazard, the
subdistribution hazard of developing a second BCC is lower
for older age, because it takes into account the fact that
people may die and therefore are no longer at risk of a second
BCC. The nonlinear relation between age at ﬁrst BCC
diagnosis and developing a second BCC could best be
approximated by adding a squared term for age to the model.
Predictors for a second BCC
Of the 13 potential predictors, a lower age at ﬁrst BCC (hazard
ratio (HR): 1.6, 95% conﬁdence interval (CI): 1.3–2.0 for 13
years younger) and two tumor-speciﬁc factors (i.e., superﬁcial
subtype of the ﬁrst BCC and more than one BCC at ﬁrst date of
diagnosis) were signiﬁcantly associated with an increased risk
of a second BCC in the univariable analyses (Table 2).
Furthermore, several other characteristics showed borderline
signiﬁcant associations with an increased risk of a new BCC,
namely male sex, easily sunburned, and truncal localization
of the ﬁrst BCC. In contrast, an increase in coffee consumption
of 3 cups per day (HR: 0.8, 95% CI: 0.6–1.0) was borderline
signiﬁcantly associated with a decreased risk of a
second BCC.
After backward selection, ﬁve predictors remained in the
reduced multivariable model: age at ﬁrst BCC, sex, coffee
consumption, superﬁcial subtype of the ﬁrst BCC, and more
Table 1. Characteristics of 1,077 patients from the Rotterdam Study with at least a ﬁrst BCC diagnosis
Patient and tumor characteristics Category Overall New BCC Death without new BCC Alive without new BCC
Number of patients 1,077 (100%) 293 (100%) 305 (100%) 479 (100%)
Follow-up time (years) Median (IQR) 3.8 (1.7–7.2) 3.0 (1.3–5.6) 4.6 (2.0–7.7) 3.8 (1.8–7.3)
Age at ﬁrst BCC (years) Median (IQR) 74.5 (67.6–80.7) 73.1 (67.3–77.6) 80.0 (74.6–85.6) 71.8 (65.4–78.7)
Sex Male 484 (45%) 143 (49%) 137 (45%) 204 (43%)
BMI (kg per m2) Median (IQR) 26.0 (23.8–28.6) 25.9 (23.8–28.1) 26.5 (24.3–29.0) 25.9 (23.7–28.4)
Missing 77 (7%) 15 (5%) 33 (11%) 29 (6%)
Pigment status Dark 174 (16%) 42 (14%) 41 (13%) 91 (19%)
Intermediate 514 (48%) 138 (47%) 135 (44%) 241 (50%)
Light 240 (22%) 75 (26%) 74 (24%) 91 (19%)
Missing 149 (14%) 38 (13%) 55 (18%) 56 (12%)
Easily sunburned Yes 365 (34%) 111 (38%) 92 (30%) 162 (34%)
Missing 68 (6%) 20 (7%) 20 (7%) 28 (6%)
Outdoor work Yes 142 (13%) 40 (14%) 50 (16%) 52 (11%)
Missing 294 (27%) 90 (31%) 43 (14%) 161 (34%)
Sun protection No or almost
never
404 (38%) 108 (37%) 133 (44%) 163 (34%)
Missing 63 (6%) 19 (6%) 19 (6%) 25 (5%)
Smoking Current or ever 705 (65%) 188 (64%) 198 (65%) 319 (67%)
Missing 18 (2%) 9 (3%) 3 (1%) 6 (1%)
Alcohol consumption (glasses per week) Median (IQR) 3.8 (0.4–11.2) 3.5 (0.5–11.2) 3.1 (0.2–11.1) 4.3 (0.3–11.2)
Missing 241 (22%) 52 (18%) 86 (28%) 103 (22%)
Coffee consumption (cups per day) Median (IQR) 3.3 (2.0–5.0) 3.3 (2.0–4.0) 4.0 (3.0–5.0) 3.3 (2.0–5.0)
Missing 241 (22%) 52 (18%) 86 (28%) 103 (22%)
Localization of ﬁrst BCC Head 663 (62%) 175 (60%) 207 (68%) 281 (59%)
Extremities 137 (13%) 35 (12%) 32 (10%) 70 (15%)
Trunk 265 (25%) 81 (28%) 59 (19%) 125 (26%)
Missing 12 (1%) 2 (1%) 7 (2%) 3 (1%)
Superﬁcial ﬁrst BCC Yes 199 (18%) 64 (22%) 39 (13%) 96 (20%)
Missing 76 (7%) 22 (8%) 34 (11%) 20 (4%)
41 BCC at ﬁrst diagnosis date Yes 132 (12%) 69 (24%) 26 (9%) 37 (8%)
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index; IQR, interquartile range.
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than one BCC at ﬁrst date of diagnosis (Table 2). None of
the UVR-related predictors were associated with a second
BCC. Being “easily sunburned” also lost its signiﬁcance after
adjustment for all other predictors. The strongest predictor
was having more than one BCC at ﬁrst date of diagnosis
(adjusted HR: 2.5, 95% CI: 1.9–3.3). Coffee consumption
remained signiﬁcantly associated with a decreased risk of a
second BCC (adjusted HR: 0.7, 95% CI: 0.6–0.9). A complete
case analysis on 567 participants resulted in the same
reduced multivariable model and comparable HRs (data not
shown).
The apparent concordance index (c-index) of the
multivariable model was 0.66 (95% CI: 0.58–0.73) at 1 year,
0.67 (95% CI: 0.62–0.72) at 3 years, and 0.65 (95% CI: 0.61–
0.69) at 5 years after ﬁrst BCC diagnosis. After correction for
optimism, the c-index of the model was 0.64 at 1 year, 0.65 at
3 years, and 0.63 at 5 years after ﬁrst BCC diagnosis. When
using the score chart for predictions, the apparent c-indices
were nearly identical to those of the original model (0.65 at 1
year, 0.67 at 3 years, and 0.65 at 5 years after ﬁrst BCC
diagnosis).
Clinical application
The observed cumulative incidence curve of the high-risk
group showed a distinct pattern compared with the observed
cumulative incidence curves of the other risk groups
(Figure 2). Table 3 shows the score chart that was based
on the shrunken regression coefﬁcients of the ﬁnal predic-
tion model; the estimated shrinkage factor was 0.88. Using
the score chart, the physician can easily calculate the
predicted risk of a second BCC for a patient currently having
a ﬁrst BCC. The patient obtains a score for each predictor,
and these are added up to form a total score. The corres-
ponding predicted risks of a second BCC (within 1, 3, and 5
years) can be found in Table 3 as well. For example, a
63-year-old (two points, when age is rounded to 65 years)
man (one point) who drinks no coffee (two points) presenting
with one (zero points) superﬁcial (one point) BCC has a total
score of 6, which corresponds to a 3-year risk of 21%.
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Figure 1. Relationships between age at ﬁrst BCC diagnosis and risk of a second BCC or death. (a) Cause-speciﬁc hazard of second BCC. Nonlinear relation
between age at ﬁrst BCC (x axis) and the logarithmic transformation of the cause-speciﬁc hazard of developing a second BCC (y axis) using a Cox model. The
dotted lines represent the 95% conﬁdence intervals. (b) Cause-speciﬁc hazard of death. Linear relation between age at ﬁrst BCC (x axis) and the logarithmic
transformation of the cause-speciﬁc hazard of dying (y axis) using a Cox model. The dotted lines represent the 95% conﬁdence intervals. (c) Subdistribution
hazard of second BCC. Non-linear relation between age at ﬁrst BCC (x axis) and the logarithmic transformation of the subdistribution hazard of developing a
second BCC (y axis) using a Fine and Gray model. The dotted lines represent the 95% conﬁdence intervals. BCC, basal cell carcinoma.
Table 2. Associations between predictors and
occurrence of a second BCC (n= 293) using the Fine
and Gray model for competing risks
Patient and tumor
characteristics Coding
Univariable
models
Multivariable
model1
Age at ﬁrst BCC
(years)
68 versus 812 1.6 (1.3–2.0)*** 1.6 (1.3–2.0)
Sex Male 1.3 (1.0–1.6)* 1.2 (0.9–1.5)
BMI (kg per m2) 24 versus 292 1.1 (0.9–1.3) —
Pigment status Dark Reference —
Intermediate 1.2 (0.8–1.6) —
Light 1.4 (0.9–2.0) —
Easily sunburned Yes 1.3 (1.0–1.6) —
Outdoor work Yes 1.1 (0.8–1.5) —
Sun protection No or almost
never
0.9 (0.7–1.2) —
Smoking Ever 1.1 (0.8–1.3) —
Alcohol
consumption
(glasses per week)3
10 versus 02 1.1 (0.8–1.6) —
Coffee
consumption (cups
per day)
5 versus 22 0.8 (0.6–1.0)* 0.7 (0.6–0.9)
Localization of ﬁrst
BCC
Head Reference —
Extremities 1.1 (0.8–1.5) —
Trunk 1.3 (1.0–1.7)* —
Superﬁcial ﬁrst BCC Yes 1.5 (1.1–2.0)** 1.3 (0.9–1.7)
41 BCC at ﬁrst
diagnosis date
Yes 2.6 (2.0–3.4)*** 2.5 (1.9–3.3)
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index.
The baseline cumulative subdistribution hazard is 0.035 at 1 year, 0.106 at
3 years, and 0.170 at 5 years.
*P-value o0.05, **P-value o0.01, and ***P-value o0.001.
1After backward selection.
2Interquartile range.
3Truncated at 10 glasses per week.
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DISCUSSION
This prospective population-based cohort study shows that
the absolute risk of a second BCC could be predicted with
reasonable accuracy using simple phenotypic, lifestyle and
tumor-speciﬁc characteristics. The strongest predictor of a
second BCC in time was having more than one BCC at initial
BCC diagnosis. Participants were 2.5-fold more likely to
develop a new BCC compared with individuals who only had
one BCC at the initial date of diagnosis. From the concept of
ﬁeld cancerization, this observation is expected. It is consistent
with the results from the Skin Cancer Prevention Study Group
and a retrospective Spanish study demonstrating that the total
number of prior BCCs was strongly associated with the risk of
metachronous BCCs (Karagas et al., 1992; Graells, 2004).
A superﬁcial subtype of the ﬁrst BCC gave a participant a
signiﬁcantly higher (+30%) risk to develop a second BCC,
which is in accordance with data from a British retrospective
cohort study (Lovatt et al., 2005). In previous studies, the
histopathological subtype of a BCC has also been associated
with tumor localization, as most of the truncal BCCs are
superﬁcial, and most of the head and neck BCCs are nodular
(Bastiaens et al., 1998; Scrivener et al., 2002). We noted a
similar pattern, suggesting a good validity of these predictors.
A nonlinear (parabolic) relationship between age at ﬁrst
BCC diagnosis and the risk of a second BCC was detected. As
expected, the risk of a second BCC increased with age, but
this risk decreased after approximately 68 years of age.
Several other cohort studies have shown a similar risk
increase with age but not a risk decrease as patients get even
older. Reasons could be that they analyzed a younger cohort
and/or changed age into a categorical variable so that a
possible nonlinear relationship was hidden (Karagas et al.,
1992; Richmond-Sinclair et al., 2010; Flohil et al., 2011).
After adjusting for other factors in the multivariable model,
male gender was a modest prognostic factor for a second
BCC. Other cohorts demonstrated weak to strong relations
between male sex and risk of a subsequent BCC, but they did
not adjust for tumor characteristics, such as histological
subtype and/or localization, that differ across gender (Karagas
et al., 1992; Richmond-Sinclair et al., 2010; Flohil et al.,
2011).
Remarkably, coffee consumption reduced the risk of a
second BCC (adjusted HR per increase in three cups per day:
0.7, 95% CI: 0.6–0.9). Although caffeinated and decaffeinated
coffee consumers could not be differentiated in the overall
population, ~ 90% of the coffee consumers in RS-I, which
accounts for most of the included participants, used
caffeinated coffee. Several observational studies investigated
the association between coffee intake and BCC development.
Recently, a large prospective follow-up study from Australia
showed protective effects of coffee consumption (Miura et al.,
2014), whereas two European case–control studies did not
ﬁnd a signiﬁcant association with BCC development (Corona
et al., 2001; Milan et al., 2003). Animal studies have shown
that oral and topical administration of caffeine inhibit UVB-
induced carcinogenesis and selectively increase apoptosis in
squamous cell carcinomas (Huang et al., 1997; Lu et al.,
2002). In vitro research on human keratinocytes has
demonstrated that this inhibitory effect of caffeine may be
due to the induction of apoptosis in UVB-damaged keratino-
cytes (Heffernan et al., 2009; Han et al., 2011). However,
people consuming more coffee may also differ from those
drinking less coffee for which the analyses were unable to
adjust for (i.e., residual confounding). A recent review argues
that coffee intake reﬂects an, often unmeasured, healthy life
style and is indirectly associated with multiple health
outcomes (Mirza et al., 2014).
It is interesting that no signiﬁcant inﬂuence was found
for pigment status and UVR-related characteristics (easily
sunburned, outdoor work, and sun protection) on the
development of a second BCC. The lack of this association
was consistent with earlier studies (Lovatt et al., 2005;
Richmond-Sinclair et al., 2010). A reason for this apparently
paradoxical observation could be the so-called index
event bias (Dahabreh and Kent, 2011). UVR is a strong risk
factor for a ﬁrst BCC, and participants who have been
exposed to high levels of UVR could have a relatively
favorable risk factor proﬁle with respect to the other known
and unknown risk factors for a ﬁrst BCC. This relatively
favorable risk proﬁle could, with respect to the other risk
factors in the statistical analysis, show a seemingly
nonsigniﬁcant or an even protective relation with the
development of a new BCC within this group with high
UVR exposure compared with the group without high levels
of UVR exposure.
The prediction model and simple score chart allow for
identiﬁcation of high-risk patients for more intensive follow-
up, while excluding the low-risk patients from subsequent
follow-up visits. This will lower the strain that the group of
BCC patients is putting on the limited (specialized) health
care. In addition, an earlier detection of BCCs most likely
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Figure 2. Observed cumulative incidence curves of the three risk groups.
Observed cumulative incidence (y axis) curves of the three risk groups (low,
intermediate, and high-risk) with follow-up time (x axis) using the 25th and
75th percentiles of the risk score distribution as cut points. Below the ﬁgure are
the numbers at risk at start of follow-up and at 1, 3, and 5 years of follow-up for
each risk group.
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leads to smaller tumor sizes, which in turn will reduce
treatment-related morbidity and costs (Mudigonda et al.,
2010). Our 1-year (0.64), 3-year (0.65), and 5-year (0.63)
discriminative ability is far from perfect, which suggests that
other (unknown) predictors also have a role in the develop-
ment of a second BCC. Combining genetic and non-genetic
predictors into one model might increase the c-index.
Limitations
Cohort members may have developed BCCs prior to the
complete national coverage of the pathology database
(PALGA) in 1991, leading to misclassiﬁcation bias, which
reduces the generalizability. However, between 1971 and
1991 partial coverage was achieved and the mean age of the
included participants in 1991 was 61 years, which is seven
years younger compared with the mean BCC age of diagnosis
(Arits et al., 2011), suggesting that the impact of this bias is at
most modest. In addition, approximately 30% of the
participants with a ﬁrst BCC developed at least a second
BCC, which is in line with another Dutch PALGA study and a
recent meta-analysis (Flohil et al., 2011; Flohil et al., 2013b),
suggesting excellent internal validity of the study design.
Because we obtained our BCC cases through a linkage with
PALGA, we have missed BCC diagnoses that were not made
based on histopathology. However, a recent study showed
that only a small percentage (ca. 7%) of patients with
metachronous BCCs had subsequent non-histologically con-
ﬁrmed BCCs (Flohil et al., 2013c). In addition, the evidence-
based guideline regarding BCC from the Dutch Society for
Dermatology and Venereology (NVDV) states that all
biopsied/excised BCCs should be sent for a histopathological
diagnosis (http://www.nvdv.nl/wp-content/uploads/2014/08/
Richtlijn-Basaalcelcarcinoom-2014.pdf).
The UVR-related items in the questionnaires for this study
may not have been optimal but probably picked up major
differences in UVR exposure between participants. Although
lifestyle characteristics may change over a lifetime, we only
measured UVR-related variables, smoking, alcohol consumption,
coffee consumption, and BMI at baseline for most partici-
pants. However, we do not believe that non-UVR-related
behavior changes after a ﬁrst BCC diagnosis, as most patients
do not associate predictors such as smoking, alcohol
consumption, and coffee consumption with BCC develop-
ment. UVR-related behavior may change, but most of the UV
damage has already been done years before diagnosis. We
Table 3. On the left, score chart for predicting an individual’s risk of a second BCC at the time of a ﬁrst BCC. On the
right, total scores and corresponding absolute risks of a second BCC at the time of a ﬁrst BCC.
Predictor Value Score Total score 1-Year risk 3-Year risk 5-Year risk
Age at ﬁrst BCC (years) ≤55 0 ≤− 5 1% 4% 6%
60 1 − 4 2% 5% 8%
65 2 − 3 2% 6% 9%
70 2 − 2 2% 6% 10%
75 1 − 1 2% 7% 11%
80 0 0 3% 9% 13%
85 − 3 1 3% 10% 16%
≥90 − 5 2 4% 11% 18%
Sex Female 0 3 5% 13% 20%
Male 1 4 5% 15% 23%
Daily intake of cups of coffee 0 2 5 6% 18% 28%
1 1 6 8% 21% 32%
2 1 ≥ 7 10% 27% 40%
3 0
4 − 1
5 − 1
≥6 −2
Superﬁcial subtype of ﬁrst BCC No 0
Yes 1
41 BCC at ﬁrst date of diagnosis No 0
Yes 5
Total score
Abbreviation: BCC, basal cell carcinoma.
The predicted risk (%) of a second BCC within 1 year after the primary BCC was determined by: P= [1−(exp(−exp(B)×0.035))]×100%, where
B=0.285× age−0.002× age2+ 0.152 (if male sex)− 0.093× coffe cups per day+ 0.209 (if superﬁcial subtype)+0.796 (if more than one BCC).
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did not have UVR exposure information during childhood and
adolescence, which is important in the etiopathogenesis of
BCC, but because of the potential recall bias this information
is often inaccurate (Glanz et al., 2010).
We have tried to ﬁnd an external cohort for validation of
our prediction model (Leiden Skin Cancer Study, Nurses’
Health Study and Framingham Heart Study). Unfortunately,
multiple BCC data and detailed information on our predictors
are scarce.
CONCLUSION
The risk factor proﬁle for a second BCC differs from that of a
ﬁrst BCC. The strongest predictor is the presentation of
multiple BCCs at index date. Other factors associated with a
second BCC are age at ﬁrst BCC, male gender, coffee con-
sumption, and superﬁcial subtype of the ﬁrst BCC. These simple
variables provide a tool to assist physicians to identify high-risk
patients, to give a tailored follow-up, and to give information on
the risk of subsequent BCCs. External validation and improve-
ment of the discriminative ability are needed.
MATERIALS AND METHODS
Study population
The RS is a prospective population-based cohort study of people
aged 45 years or older (Hofman et al., 2013). From July 1989 to
September 1993, the ﬁrst cohort of 7,983 recruited persons (RS-I,
78% of the invitees) aged 55 years or older was realized. In 2000–
2001, another 3,011 participants (RS-II, 67% of the invitees) who had
become 55 years of age or older, or applied to this age minimum and
had moved into the district, were added to the cohort. The last
addition of 3,932 Ommoord inhabitants (RS-III, 65% of the invitees)
aged 45–54 years took place during 2006–2008. These three cohorts
together comprise 14,926 participants. Data were acquired by
interviews at home and by thorough examinations in a specially
built research facility in their district. These examinations were
repeated every 3–4 years. The RS has been approved by the Medical
Ethics Committee of the Erasmus MC and by the Ministry of
Health, Welfare and Sport of The Netherlands, implementing
the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: RS).
All participants provided written informed consent to participate in
the study and to obtain information from their treating physicians.
The RS was conducted according to the Declaration of Helsinki
Principles.
Case deﬁnition
The RS participants were linked to the Dutch nationwide network
and registry of histopathology and cytopathology (PALGA) to retrieve
their medical history of histopathologically conﬁrmed BCCs. PALGA
was founded in 1971 and achieved complete national coverage in
1991 (i.e., since 1991 all Dutch histopathology laboratories are
linked to this databank; Casparie et al., 2007). Every pathology
excerpt located on PALGA’s central databank contains encrypted
patient data and a PALGA diagnosis line derived from the
Systematized Nomenclature of Medicine. In collaboration with a
dermatopathologist, the following information from the excerpts was
retrieved: date of diagnosis, anatomical location, body side, type of
procedure (i.e., biopsy or excision), radicality, and diagnosis (includ-
ing tumor subtype). To obtain all pathology reports concerning BCC,
we used the PALGA diagnosis lines attached to all subtypes of BCC
(i.e., M80903, M80913, M80923, M80933, M80943, M80963,
M80973, and M80983).
The linkage was done using encrypted patient data both available
in the RS and PALGA. This encrypted data consisted of the patient’s
date of birth, gender, and ﬁrst four to eight letters of the (maiden)
family name. The combination of these identiﬁers produced a linkage
key. This key showed 98% sensitivity and 98% positive predictive
value in earlier record linkage research (Van den Brandt et al., 1990).
Of the 14,926 RS participants, 298 did not sign informed consent
for a linkage and could not be linked to PALGA. Every BCC excerpt
between 1 July 1989 and 31 December 2013 was retrieved from the
network of PALGA. Participants who had developed a BCC before
entering the RS were excluded from the analyses.
All excerpts mentioned a date of diagnosis, and, the majority of
excerpts included a precise anatomical location and information
about the type of procedure and the radicality of the excision, which
made it possible to distinguish between different BCCs over time. If
information about location was not available, we assumed that a
biopsy followed by an excision within a logical time frame
(o3 months) concerned the same BCC.
The next tumor following a radical excision was always scored as a
new BCC. If an excision was irradical, the next reported tumor on the
same or adjacent location was regarded as the same tumor.
Metachronous BCCs occurring within 6 months of the ﬁrst BCC
were counted as additional tumors at the date of the initial diagnosis,
as those BCCs were most likely present at this earlier date. If a BCC
consisted of different histopathological subtypes, a superiority rule
was used, namely inﬁltrative greater than micronodular greater than
nodular greater than superﬁcial. Unclear excerpts were discussed
with an experienced dermatologist, and, if available, missing
information was obtained from medical records.
Candidate predictors
Three phenotypic factors were selected—namely, age at ﬁrst BCC
(years), sex, and pigment status (Robinson, 1987; Karagas et al.,
1992). The latter was a combination of eye color and hair color when
young (e.g., a participant with blue eyes and red hair was scored as
light). Hair color for RS-III was determined during the second
examination round.
Three questions related to UVR exposure were selected and
concerned the tendency to develop sunburn, a history of outdoor
work for at least 4 hours per day during at least 25 years, and sun
protective behavior measured by wearing sunglasses or a hat
(Karagas et al., 1992). A history of outdoor work was not included
in the questionnaire for the RS-II cohort. All UVR-related questions
for RS-III were determined during the second examination round. In
addition, smoking, alcohol consumption (glasses per week), coffee
consumption (cups per day), and BMI (kg m− 2) were selected as
other lifestyle factors (Freedman et al., 2003; Gerstenblith et al.,
2012; Miura et al., 2014). Alcohol and coffee consumption for RS-II
were determined during the third examination round.
Finally, three variables concerning BCC characteristics were
included: localization of the ﬁrst BCC, superﬁcial histopathological
subtype of the ﬁrst BCC, and the number of BCCs at ﬁrst date of
diagnosis (Karagas et al., 1992; Lovatt et al., 2005).
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Model development
All included participants had at least a ﬁrst BCC and therefore have a
date of ﬁrst BCC diagnosis that served as starting point of the follow-
up. Participants were followed from this point forward until they
developed a second BCC, died, or reached the end of the linkage
period (31 December 2013) without developing a subsequent BCC.
Mortality dates were obtained from the municipal register. The
localization and histopathological subtype of the ﬁrst BCC of
participants who had more than one BCC at the ﬁrst date of diagnosis
were randomly selected before the analyses.
Missing predictor values were imputed 50 times using multivariate
imputation by chained equations (Van Buuren, 2012). The
imputation model included all candidate predictors, the outcome
(i.e., second BCC or censored), the follow-up time, the side of the ﬁrst
BCC, the level of education, and the RS cohort number.
As a large proportion (28%) of the elderly participants with a
ﬁrst BCC died before they could have developed a second BCC,
the analyses were adjusted for competing risk of death from
other causes (Wolbers et al., 2009). We used the Fine and Gray
semiparametric proportional hazards model to estimate univariable
and multivariable regression coefﬁcients (Fine and Gray, 1999).
The subdistribution hazard of the event of interest (i.e., second BCC)
is the absolute risk of a second BCC. We explored the association
of the continuous predictors with the risk of metachronous BCCs
by plotting several transformations (e.g., linear, natural logarithm, or
square).
We entered all (possibly transformed) candidate predictors in a
multivariable model, independent of their p-values in the univariable
models. To reduce the multivariable model with backward stepwise
selection, we used Wald tests based on Rubin’s rules for combining
estimated regression coefﬁcients and variances from the 50 different
completed data sets (Vergouwe et al., 2010). To reduce selection bias,
we used a liberal P-valueo0.20 to include predictors (Steyerberg et al.,
2000; Steyerberg, 2009). No signiﬁcant interactions were observed
among the included predictors. The regression coefﬁcients in the ﬁnal
model were multiplied with a shrinkage factor, which was estimated
with bootstrapping (Steyerberg, 2009). Shrinkage was applied to prevent
that predictions for new patients were too extreme (i.e., low predictions
being too low and high predictions being too high).
We performed a sensitivity analysis by including only participants
with complete data in the multivariable modeling.
Model performance
We focused on discrimination as a key aspect of model performance.
The discriminative ability of the model was evaluated using the c-index.
In the available survival data, the c-index represents the probability that,
for a randomly chosen pair of patients, the patient who experiences a
second BCC earlier in time has a higher predicted risk. A c-index of 0.5
is equivalent to a coin toss, whereas 1.0 implies perfect predictability.
We corrected the c-indices for optimism using a bootstrap procedure
(500 replications; Steyerberg, 2009).
Clinical application
For illustrative purposes, we divided patients in three risk groups
(low, intermediate, and high) using the 25th and 75th percentiles of
the risk score distribution as cut points. Next, a score chart was
developed to facilitate clinical application of the ﬁnal prediction
model. Scores were based on the shrunken regression coefﬁcients,
which were multiplied by 6.7 and then rounded to an integer. A
constant was subtracted or added to rescale the scores conveniently.
IBM SPSS Statistics for Windows version 21.0 (Chicago, IL) was
used for data management and R version 3.1.1 for more advanced
statistical analysis (R Core Team, 2013), using the cmprsk and
riskRegression libraries.
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